MADISON, Wis., Feb. 8, 2017 /PRNewswire/ -- Propeller
Health, the leading digital health solution for respiratory
medicine, and Novartis Pharma AG (NYSE: NVS) today announced a
collaboration to develop a custom add-on sensor for the
Breezhaler™ inhaler, a device used for the company's
portfolio of COPD treatments
(Ultibro™ Breezhaler™,
Onbrez™ Breezhaler™ and
Seebri™ Breezhaler™), connecting
these medications to Propeller's digital health platform.
As patients use the Breezhaler™ inhaler, a patented
capsule-based dry powder inhaler (DPI) for treatment of COPD, the
new custom sensors will allow for passively recording and
transmitting compliance data, better informing patients and their
physicians of adherence and other treatment factors through the
Propeller platform. Propeller has regulatory clearance to help
patients and their physicians better understand asthma and COPD,
and help to improve the symptoms and outcomes of these chronic
respiratory diseases. The Novartis-Propeller partnership is focused
on COPD in Europe.
"We're excited to work with the team at Novartis to connect the
Breezhaler™ device to the Propeller platform. The
addition of this major respiratory franchise represents an
important next step in our mission to bring valuable digital
companions to everyone's respiratory treatments," said David Van Sickle, CEO, Propeller Health. "With
data from these medication sensors and interfaces, Propeller
strengthens the relationships between patients and their physicians
and helps them build effective treatment programs together."
With the majority of inhaled medications now connected to its
software platform, Propeller has grown significantly over the last
12 months with over 45 programs signed with leading healthcare
systems such as Dignity Health and Nemours Children's Health
System, managed care organizations such as Molina Healthcare and
innovative at-risk entities such as ChenMed. This growth has been
driven by rapid adoption of its platform among pharmaceutical
manufacturers and the country's largest payers and healthcare
providers, who seek a better approach to asthma and COPD
management. New program starts and the expansion of existing
programs, such as with industry leading innovator Dignity Health,
have been driven by strong clinical and financial results seen
across programs, and from large-scale clinical trials published in
the peer-reviewed literature.
About Propeller Health
In 2010, Propeller set out to modernize respiratory medicine,
help people minimize the impact of asthma and COPD on their daily
lives, and connect them to their physicians, environment and
community. Propeller's information-powered approach to respiratory
management guides physicians and patients to the optimal path of
therapy for each individual. With connected inhalers, digital
interfaces, mobile spirometers and real-time personalized insights,
participants receive personal guidance and expert direction
anytime. Backed by 3M Ventures (NYSE: MMM), SR One, Hikma Ventures
(LON: HIK), Safeguard Scientifics (NYSE: SFE), Social Capital and
other investors, Propeller has been used by patients with asthma or
COPD in over 45 commercial programs across the US at major
healthcare systems, payers, employers and other commercial
partners. The company has been recognized as the recipient of the
American Telemedicine Association's 2016 President's Award for
Innovation in Remote Healthcare and as one of the top "Fierce 15"
medical device companies in 2015 by FierceMedicalDevices. For more
information visit: www.propellerhealth.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/propeller-health-enters-into-collaboration-to-connect-breezhaler-devices-to-the-propeller-platform-300404118.html
SOURCE Propeller Health